Precision BioSciences, Inc. filed a Form 8-K on November 9, 2026, disclosing details of a public offering of common stock and pre-funded warrants entered into on November 5, 2026, along with the company's projected cash runway through the fourth quarter of 2029.

Key Highlights

  • Shares offered: 10,235,077 shares of common stock at $7.75 per share, according to the filing.
  • Pre-funded warrants: Up to 5,893,964 shares available via pre-funded warrants priced at $7.749995 per warrant, in lieu of common stock to certain investors.
  • Par value: Common stock carries a par value of $0.000005 per share.
  • Cash runway projection: The company projects net proceeds combined with existing cash, fiscal discipline, and its at-the-market facility will provide cash runway into the fourth quarter of 2029.
  • Clinical programs: The company projects it is "sufficiently capitalized to fund both PBGENE-HBV and PBGENE-DMD clinical programs through key next stage inflection points."
  • Underwriting agreement date: The underwriting agreement was entered into on November 5, 2026.

Precision BioSciences Discloses November 2026 Offering Terms and Runway Outlook

Precision BioSciences, Inc. (NASDAQ:DTIL), headquartered in Durham, North Carolina, filed a Form 8-K current report dated November 9, 2026, under Item 8.01 Other Events. The filing describes an offering entered into on November 5, 2026, in which the company agreed to issue and sell 10,235,077 shares of its common stock at $7.75 per share. For certain investors, the company offered pre-funded warrants to purchase up to 5,893,964 shares at $7.749995 per pre-funded warrant in lieu of common stock, according to the filing.

The filing states that the company expects net proceeds from the offering, together with existing cash and cash equivalents, "continued fiscal and operating discipline," and availability of its at-the-market facility, will provide sufficient cash runway into the fourth quarter of 2029. The company further projects it is "sufficiently capitalized to fund both PBGENE-HBV and PBGENE-DMD clinical programs through key next stage inflection points," as stated in the disclosure.

The filing notes that statements regarding the sufficiency of cash runway and the ability to fund clinical programs are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and are subject to known and unknown risks and uncertainties. The company references its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and its Quarterly Reports on Form 10-Q for periods ended March 31, 2026, June 30, 2026, and September 30, 2026 as sources of applicable risk factors. The filing was signed by Naresh Tanna, Chief Financial Officer, on November 9, 2026.

What Was Disclosed

Precision BioSciences disclosed the terms of a November 5, 2026 underwriting agreement covering 10,235,077 shares at $7.75 per share and pre-funded warrants for up to 5,893,964 shares at $7.749995 each, along with a projected cash runway extending into the fourth quarter of 2029.